Young Wendy B. reported grant involving 25,666 derivative units of ADIAL PHARMACEUTICALS, INC. at $0.00 for $0 on Sep 17, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Director
DIR
Filed Sep 21, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
25,666Stock Option (Right to Buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
25,666Direct
Trade date
Sep 17, 2026Grant
Filed
Sep 21, 2026, 7:25 PM ET4-day reporting delay
Accession
0001213900-26-101883Code A · Transaction 227177
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

ADIL price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
ADIL · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Sep 28, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago1w ago1d ago
Returns since7d30d90d180d1y

Footnotes in full

F1: On June 11, 2026, the Issuer's board of directors approved the option grant issued to the Reporting Person on June 12, 2026, which grant was subject to stockholder approval of an amendment to the Issuer's 2017 Equity Incentive Plan to increase the number of shares authorized for issuance thereunder. The Issuer's stockholders approved the plan amendment on September 17, 2026 ("Stockholder Approval Date"). F2: 2,138 shares subject to the stock option vested on the Stockholder Approval Date and the remaining 23,528 shares subject to the stock option shall vest in substantially equal installments over a 33-month period, beginning on October 12, 2026.